Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: The START*study

International Journal of Clinical Practice

Volumn 64, Issue 7, 2010, Pages 936-943

  Lanteri Minet, M ^a   Diaz Insa S ^b   Leone, M ^c   Vila, C ^d   Clissold, S P ^e  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b HOSPITAL FRANCESC DE BORJA   (Spain)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d Almirall SA ^*  (Spain)

^e Content Ed Net ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; PARACETAMOL; PLACEBO;

ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FRANCE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PATIENT EDUCATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPAIN; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; ANALGESICS; DISABLED PERSONS; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PATIENT EDUCATION AS TOPIC; PROSPECTIVE STUDIES; RECURRENCE; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 77952688368     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02379.x     Document Type: Article

References (27)

1. World Health Organization. The Global Burden of Disease: 2004 Update. http://www.who.int/healthinfo/global-burden-disease/2004-report-update/en/index. html (accessed February 2009).
2. Tfelt-Hansen P, Saxena PR, Dahlöf C et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000a 123 (Pt 1 9 18.
3. Tfelt-Hansen P, Block G, Dahlöf C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000b 20: 765 786.
4. Ng-Mak DS, Cady R, Chen YT et al. Can migraineurs accurately identify their headaches as 'migraine' at attack onset? Headache 2007 47: 645 653.
5. Gendolla A. Early treatment in migraine: how strong is the current evidence? Cephalalgia 2008 28 (Suppl. 2 28 35.
6. Goadsby PJ, Zanchin G, Geraud G et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)' A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008 28: 383 391.
7. Shapero G, Dowson A, Lacoste JP, Almqvist P. Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet. Int J Clin Pract 2006 60: 1530 1535.
8. Lucas C, Géraud G, Valade D et al. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 2006 46: 715 725.
9. [RCGP 2009] Royal College of General Practitioners, the Office of Population Censuses and Surveys, Department of Health. Morbidity Statistics from General Practice Fourth national study 1991-1992. Series MB5 no.3. http://www.statistics.gov.uk/downloads/theme-health/MB5No3.pdf (accessed July 2009).
10. Edmeads J. Why is migraine so common? Cephalalgia 1998 18 (Suppl. 22 2 4.
11. Latinovic R, Gulliford M, Ridsdale L. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry 2006 77: 385 387.
12. Hasse LA, Ritchey PN, Smith R. Predicting the number of headache visits by type of patient seen in family practice. Headache 2002 42: 738 746.
13. Krobot KJ, Schröder-Bernhardi D, Pfaffenrath V. Migraine consultation patterns in primary care. Results from the PCAOM study 1994-96. Cephalalgia 1999 19: 831 840.
14. Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M. FRAMIG 2000: medical and therapeutic management of migraine in France. Cephalalgia 2005 25: 267 279.
15. Ridsdale L, Clark LV, Dowson AJ et al. How do patients referred to neurologists for headache differ from those managed in primary care? Br J Gen Pract 2007 57: 388 395.
16. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001 41: 638 645. (Pubitemid 32777746) (Pubitemid 32777746)
17. De Klippel N, Jansen JP, Carlos JS. Survey to evaluate diagnosis and management of headache in primary care: Headache Management Pattern Programme. Curr Med Res Opin 2008 24 (12 3413 3422.
18. [CPMP 2007] Committee For Medicinal Products For Human Use (CHMP) Guideline On Clinical Investigation Of Medicinal. Guideline on Clinical Investigation of Medicinal Products For The Treatment Of Migraine. CPMP/EWP/788/01 Rev. 1, January 2007. http://www.emea.europa.eu/pdfs/human/ewp/ 078801enfin.pdf (accessed July 2009).
19. Bendtsen L, Mattsson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003 23: 487 490.
20. Antonaci F, Chimento P, Diener HC et al. Lessons from placebo effects in migraine treatment. J Headache Pain 2007 8: 63 6.
21. Solomon S. A review of mechanisms of response to pain therapy: why voodoo works. Headache 2002 42: 656 662.
22. Rosenzweig P, Brohier S, Zipfel A. The placebo effects on healthy volunteers: influence of experimental conditions on the adverse event profile during phase I studies. Clin Pharmacol Ther 1993 54: 578 583.
23. [GCP 2009]. Good Clinical Practice: Consolidated Guideline. http://www.ich.org (accessed July 2009).
24. [IHS 2004] Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edn. Cephalalgia 2004 24 (Suppl. 1 1 160.
25. Géraud G, Lanteri-Minet M, Lucas C, on behalf of the French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004 26: 1305 1318.
26. Freitag FG, Finlayson G, Rapoport AM et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache 2007 47: 519 530.
27. Pryse-Phillips W, Aubé M, Bailey P et al. A clinical study of migraine evolution. Headache 2006 46: 1480 1486.